Chunde M. Bao
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
ANK1 and EPB41 Variants and The Risk of Glucocorticoid-Induced Osteonecrosis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 06, 2025
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
Journal: The New England journal of medicine
Published: October 15, 2025
Single-cell transcriptomics reveal potent extrafollicular B cell response linked with granzyme K+ CD8 T cell activation in lupus kidney.
Journal: Annals of the rheumatic diseases
Published: March 27, 2024
Correction: Iguratimod attenuated fbrosis in systemic sclerosis via targeting early growth response 1 expression.
Journal: Arthritis research & therapy
Published: January 23, 2024
Emerging and comparative genomic analysis of a novel plasmid carrying blaKPC-2 in Citrobacter freundii
Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Published: January 08, 2024
The SMILE study: Study of long-term methotrexate and iguratimod combination therapy in early rheumatoid arthritis.
Journal: Chinese medical journal
Published: October 29, 2023
Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression.
Journal: Arthritis research & therapy
Published: February 01, 2023
Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.
Journal: Rheumatology (Oxford, England)
Published: January 13, 2023
Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study.
Journal: Frontiers in immunology
Published: October 06, 2022
Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease.
Journal: Rheumatology (Oxford, England)
Published: June 13, 2022
Last Updated: 09/26/2026